Efficacy of a single intravesical treatment with Ad-IFN/Syn 3 is dependent on dose and urine IFN concentration obtained: Implications for clinical investigation

Cancer Gene Therapy

Volumn 13, Issue 2, 2006, Pages 125-130

  Tao, Z ^a   Connor, R J ^b   Ashoori, F ^a   Dinney, C P N ^a   Munsell, M ^a   Philopena, J A ^b   Benedict, W F ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Bladder cancer; Interferon; Intravesical therapy

Indexed keywords

ADENOVIRUS VECTOR; ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; EXCIPIENT; GREEN FLUORESCENT PROTEIN; SYN 3; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BLADDER CARCINOMA; CANCER REGRESSION; CANCER SIZE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DRUG DETERMINATION; DRUG EFFICACY; DRUG URINE LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE CONSTRUCT; GENE EXPRESSION; GENE TRANSFER; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUPERFICIAL CANCER; VIRAL GENE DELIVERY SYSTEM;

ADMINISTRATION, INTRAVESICAL; ANIMALS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE THERAPY; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HUMANS; INTERFERON-ALPHA; MICE; NEUROPEPTIDES; PHOSPHOPROTEINS; URINARY BLADDER NEOPLASMS;

ADENOVIRIDAE; ANIMALIA;

EID: 30944446391     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700865     Document Type: Article

References (14)

1. Herr HW. Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) tumors: 15-year outcome. J Urol 2000; 163: 60-61.
2. Dalbagni G, Herr HW. Current use and questions concerning intravesical bladder. Cancer Group for Superficial Bladder Cancer. Urol Clin North Am 2002; 27: 137-146.
3. O'Donnell MA, Krohn J, DeWolf WC. Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed. J Urol 2001; 166: 1300-1304.
4. Izawa JI, Sweeney P, Perrotte P, Kedar D, Dong Z, Slaton JW et al. Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis. Clin Cancer Res 2002; 8: 1258-1270.
5. Connor RJ, Engler H, Machemer T, Philopena JM, Horn MT, Sutjipto S et al. Identification of polyamides that enhance adenovirus-mediated gene expression in the urothelium. Gene Therapy 2001; 8: 41-48.
6. Yamashita M, Rosser CJ, Zhou JH, Zhang XQ, Connor RJ, Engler H et al. Syn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene therapy of genetically altered urothelium and superficial bladder cancer. Cancer Gene Ther 2002; 9: 687-691.
7. Watanabe T, Shinohara N, Sazawa A, Harabayashi T, Ogiso Y, Koyanagi T et al. An improved intravesical model using human bladder cancer cell lines to optimize gene and other therapies. Cancer Gene Ther 2002; 7: 1575-1580.
8. Zhou JH, Rosser CJ, Tanaka M, Yang M, Baranov E, Hoffman RM et al. Visualizing superficial human bladder cancer cell growth in vivo by green fluorescent protein expression. Cancer Gene Ther 2002; 9: 681-686.
9. Benedict WF, Tao Z, Kim CS, Zhang X, Zhou JH, Adam L et al. Intravesical Ad-IFNα causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-α protein. Mol Ther 2004; 10: 525-532.
10. Streuli M, Hall A, Boll W, Stewart WE, Nagata S, Weissmann C. Target cell specificity of two species of human interferon-alpha produced in Escherichia coli and of hybrid molecules derived from them. Proc Natl Acad Sci USA 1981; 78: 2848-2852.
11. Rehberg E, Kelder B, Hoal EG, Pestka S. Specific molecular activities of recombinant and hybrid leukocyte interferons. J Biol Chem 1982; 257: 11497-11502.
12. Ahmed CM, Wills KN, Sugarman BJ, Johnson DE, Ramachandra M, Nagabhushan TL et al. Selective expression of nonsecreted interferon by an adenoviral vector confers antiproliferative and antiviral properties and causes reduction of tumor growth in nude mice. J Interferon Cytokine Res 2001; 21(6): 399-408.
13. Iqbal-Ahmed CM, Johnson DE, Demers GW, Engler H, Howe JA, Wills KN et al. Interferon alpha2b gene delivery using adenoviral vector causes inhibition of tumor growth in xenograft models from a variety of cancers. Cancer Gene Ther 2001; 8: 788-795.
14. Conover WJ. Practical Nonparametric Statistics, 3rd edn. New York: John Wiley & Sons, Inc., 1999.